Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2014 1
2017 1
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A, Patrucco E, Goodhart G, Dilly J, Gindin Y, Dinglasan N, Wang Y, Lai LP, Cai S, Jiang L, Nasholm N, Shifrin N, Blaj C, Shah H, Evans JW, Montazer N, Lai O, Shi J, Ahler E, Quintana E, Chang S, Salvador A, Marquez A, Cregg J, Liu Y, Milin A, Chen A, Ziv TB, Parsons D, Knox JE, Klomp JE, Roth J, Rees M, Ronan M, Cuevas-Navarro A, Hu F, Lito P, Santamaria D, Aguirre AJ, Waters AM, Der CJ, Ambrogio C, Wang Z, Gill AL, Koltun ES, Smith JAM, Wildes D, Singh M. Holderfield M, et al. Among authors: mira a. Nature. 2024 Apr 8. doi: 10.1038/s41586-024-07205-6. Online ahead of print. Nature. 2024. PMID: 38589574
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer.
Ricciuti B, Mira A, Andrini E, Scaparone P, Michelina SV, Pecci F, Cantini L, De Giglio A, Lamberti G, Ambrogio C, Metro G. Ricciuti B, et al. Among authors: mira a. Drugs Context. 2022 Nov 16;11:2022-7-4. doi: 10.7573/dic.2022-7-4. eCollection 2022. Drugs Context. 2022. PMID: 36452878 Free PMC article. Review.
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.
Ricciuti B, Son J, Okoro JJ, Mira A, Patrucco E, Eum Y, Wang X, Paranal R, Wang H, Lin M, Haikala HM, Li J, Xu Y, Alessi JV, Chhoeu C, Redig AJ, Köhler J, Dholakia KH, Chen Y, Richard E, Nokin MJ, Santamaria D, Gokhale PC, Awad MM, Jänne PA, Ambrogio C. Ricciuti B, et al. Among authors: mira a. Clin Cancer Res. 2022 Apr 14;28(8):1640-1650. doi: 10.1158/1078-0432.CCR-21-2719. Clin Cancer Res. 2022. PMID: 35091439 Free PMC article.
A non-dividing cell population with high pyruvate dehydrogenase kinase activity regulates metabolic heterogeneity and tumorigenesis in the intestine.
Sebastian C, Ferrer C, Serra M, Choi JE, Ducano N, Mira A, Shah MS, Stopka SA, Perciaccante AJ, Isella C, Moya-Rull D, Vara-Messler M, Giordano S, Maldi E, Desai N, Capen DE, Medico E, Cetinbas M, Sadreyev RI, Brown D, Rivera MN, Sapino A, Breault DT, Agar NYR, Mostoslavsky R. Sebastian C, et al. Among authors: mira a. Nat Commun. 2022 Mar 21;13(1):1503. doi: 10.1038/s41467-022-29085-y. Nat Commun. 2022. PMID: 35314684 Free PMC article.
Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.
Maione F, Oddo D, Galvagno F, Falcomatà C, Pandini M, Macagno M, Pessei V, Barault L, Gigliotti C, Mira A, Corti G, Lamba S, Riganti C, Castella B, Massaia M, Rad R, Saur D, Bardelli A, Di Nicolantonio F. Maione F, et al. Among authors: mira a. Mol Oncol. 2024 Feb 13. doi: 10.1002/1878-0261.13595. Online ahead of print. Mol Oncol. 2024. PMID: 38348572 Free article.
Four individually druggable MET hotspots mediate HGF-driven tumor progression.
Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, Morello V, Dreier T, Saunders M, de Haard H, Michieli P. Basilico C, et al. Among authors: mira a. J Clin Invest. 2014 Jul;124(7):3172-86. doi: 10.1172/JCI72316. Epub 2014 May 27. J Clin Invest. 2014. PMID: 24865428 Free PMC article.